Ocugen Inks Binding Term Sheet for OCU400 Gene Therapy License in MENA, Unlocking Up to $255M in Milestones
OCGN sits 59% above its 52-week low of $0.931.
Summary
Ocugen signed a binding term sheet to license OCU400 in the MENA region, with up to $255M in sales milestones and a 22% royalty, marking a significant partnership for its lead gene therapy candidate.
Key Events · M&A and Partnerships · OCGN
-
MENA License Deal Signed
A binding term sheet grants Roots Pharmaceutical exclusive rights to OCU400 in the Middle East and North Africa, with a definitive agreement expected within 90 days.
-
Up to $255M in Milestones
The deal includes up to $4M in upfront and near-term milestone payments, up to $255M in sales milestones, and a 22% royalty on net sales, with Ocugen manufacturing commercial supply.
-
Pipeline Validation
This partnership validates OCU400's commercial potential in a region with high RP prevalence, adding a non-dilutive funding source as the therapy advances toward a Phase 3 topline readout in Q1 2027.
-
Strategic Context
The deal follows recent capital raises totaling $130M in convertible notes and a CMO departure, providing a positive pipeline catalyst amid ongoing clinical development.
Analysis · OCGN · Life Sciences
A binding term sheet has been signed to license OCU400, a gene therapy for retinitis pigmentosa, to Roots Pharmaceutical across the Middle East and North Africa. The agreement brings up to $4 million in upfront and near-term milestone payments, up to $255 million in sales milestones, and a 22% royalty on net sales. This material partnership validates OCU400's commercial promise and delivers non-dilutive capital, though a definitive agreement is still pending within 90 days. The announcement arrives on the heels of several capital raises and a recent CMO departure, injecting a positive pipeline catalyst.
At the time of this filing, OCGN was trading at $1.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $497.6M. The 52-week trading range was $0.93 to $2.73. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.